Uncontrol trial of rituximab treatment on steroid dependent and frequently relapsing minimal cahnge nephrotic syndrome(MCNS)

Uncontrol trial of rituximab treatment on steroid dependent and frequently relapsing minimal cahnge nephrotic syndrome(MCNS) - Uncontrol trial of rituximab treatment on steroid dependent and frequently relapsing minimal cahnge nephrotic syndrome(MCNS)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005231

Enrollment

Registered

2011-03-10

Start date

2011-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

steroid dependent and frequently relapsing minimal change nephrotic syndrome

Interventions

rituximab 375mg/m2 single-dose 1 time/6months 24 months follow up

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: steroid dependent and frequently relapsing nephrotic syndrome patients, minimal change disease on biopsy, patients gave written informed consent for participation in the study

Exclusion criteria

Exclusion criteria: positive serology for hepatitis B and C, HIV and antinuclear antibodies, sereve renal dysfunction and liver dysfunction, pregnant woman

Design outcomes

Primary

Measure	Time frame
relapse the cumlative dose of prednisolone the cumulative dose of cyclosporin	—

Secondary

Measure	Time frame
the adverse effect of prednisolone the adverse effect of cyclosporin the adverse effect of rituximab	—

Countries

Japan

Contacts

Public ContactYuk Iwabuchi

Kidney Center, Tokyo Women&#39;s Medical University Department of Medicine

yukko_iwa_010005@yahoo.co.jp03-3353-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026